GETI.B

187.5

+1.65%↑

EKTA.B

55.55

+3.64%↑

ATT

100.8

+0.9%↑

AMBEA

132.3

+0.76%↑

ARJOB

25.06

+1.87%↑

GETI.B

187.5

+1.65%↑

EKTA.B

55.55

+3.64%↑

ATT

100.8

+0.9%↑

AMBEA

132.3

+0.76%↑

ARJOB

25.06

+1.87%↑

GETI.B

187.5

+1.65%↑

EKTA.B

55.55

+3.64%↑

ATT

100.8

+0.9%↑

AMBEA

132.3

+0.76%↑

ARJOB

25.06

+1.87%↑

GETI.B

187.5

+1.65%↑

EKTA.B

55.55

+3.64%↑

ATT

100.8

+0.9%↑

AMBEA

132.3

+0.76%↑

ARJOB

25.06

+1.87%↑

GETI.B

187.5

+1.65%↑

EKTA.B

55.55

+3.64%↑

ATT

100.8

+0.9%↑

AMBEA

132.3

+0.76%↑

ARJOB

25.06

+1.87%↑

Home・Elenco Azioni・Vivesto AB

Vivesto AB

Chiusa

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

Metriche Chiave
By Trading Economics
Entrata	-1.9M -9.1M
EPS	-0.015
Dipendenti	4
EBITDA	-1.8M -8.9M

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	37M 89M
Apertura precedente	0
Chiusura precedente	0

Vivesto AB Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 mar 2026, 23:15 UTC

Principali Notizie su Eventi

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mar 2026, 22:36 UTC

Principali Notizie su Eventi

Australian Government Rules Out Boots on the Ground in the Middle East

30 mar 2026, 22:13 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mar 2026, 21:00 UTC

Utili

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mar 2026, 20:15 UTC

Principali Notizie su Eventi

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mar 2026, 23:40 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 23:40 UTC

Discorsi di Mercato

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mar 2026, 23:36 UTC

Discorsi di Mercato

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mar 2026, 23:12 UTC

Discorsi di Mercato

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mar 2026, 22:49 UTC

Discorsi di Mercato

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mar 2026, 22:44 UTC

Discorsi di Mercato

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mar 2026, 22:43 UTC

Discorsi di Mercato

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mar 2026, 22:42 UTC

Discorsi di Mercato

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mar 2026, 22:18 UTC

Discorsi di Mercato

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mar 2026, 22:05 UTC

Discorsi di Mercato

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mar 2026, 21:58 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mar 2026, 21:39 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mar 2026, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mar 2026, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mar 2026, 21:25 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 21:25 UTC

Discorsi di Mercato

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mar 2026, 21:03 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mar 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

30 mar 2026, 20:09 UTC

Utili

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mar 2026, 20:00 UTC

Principali Notizie su Eventi

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Confronto tra pari

Modifica del prezzo

Vivesto AB Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.